Donor lymphocyte infusion after allogeneic stem cell transplantation. Issue 3 (June 2016)

• Record Type: Journal Article
• Authors: Castagna, Luca; Sarina, Barbara; Bramanti, Stefania; Perseghin, Paolo; Mariotti, Jacopo; Morabito, Lucio
• Is Part Of: Transfusion and apheresis science. Volume 54:Issue 3(2016)
• Page Start: 345
• Page End: 355
• Publication Date: 2016-06
• Subjects: DLI -- Allogeneic transplantation -- Relapse -- Pre-emeptive -- Hematological disease; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2016.05.011
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.